Cipher Pharmaceuticals Inc. (CPH.TO)
CAD 14.04
(-2.23%)
CAD 14.04
(-2.23%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 259 Thousand USD | -20.8% |
| 2022 | 327 Thousand USD | -28.91% |
| 2021 | 460 Thousand USD | -73.13% |
| 2020 | 1.71 Million USD | -5.99% |
| 2019 | 1.82 Million USD | -80.83% |
| 2018 | 9.5 Million USD | -17.07% |
| 2017 | 11.45 Million USD | -68.51% |
| 2016 | 36.37 Million USD | 5.2% |
| 2015 | 34.57 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 638.02 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 228 Thousand USD | 0.0% |
| 2024 Q2 | 200 Thousand USD | 0.0% |
| 2023 Q4 | 259 Thousand USD | 2.78% |
| 2023 Q3 | 252 Thousand USD | -10.64% |
| 2023 FY | 259 Thousand USD | -20.8% |
| 2023 Q1 | 302 Thousand USD | -7.65% |
| 2023 Q2 | 282 Thousand USD | -6.62% |
| 2022 Q4 | 327 Thousand USD | -7.1% |
| 2022 FY | 327 Thousand USD | -28.91% |
| 2022 Q1 | 467 Thousand USD | 1.52% |
| 2022 Q2 | 452 Thousand USD | -3.21% |
| 2022 Q3 | 352 Thousand USD | -22.12% |
| 2021 Q3 | - USD | -100.0% |
| 2021 FY | 460 Thousand USD | -73.13% |
| 2021 Q2 | 1.68 Million USD | -0.71% |
| 2021 Q4 | 460 Thousand USD | 0.0% |
| 2021 Q1 | 1.69 Million USD | -0.82% |
| 2020 Q1 | 1.62 Million USD | -10.71% |
| 2020 Q3 | 1.66 Million USD | 0.3% |
| 2020 Q4 | 1.71 Million USD | 2.7% |
| 2020 FY | 1.71 Million USD | -5.99% |
| 2020 Q2 | 1.66 Million USD | 2.21% |
| 2019 Q1 | 7.53 Million USD | -20.68% |
| 2019 Q4 | 1.82 Million USD | -57.49% |
| 2019 Q3 | 4.28 Million USD | -49.3% |
| 2019 Q2 | 8.45 Million USD | 12.14% |
| 2019 FY | 1.82 Million USD | -80.83% |
| 2018 Q2 | 13.41 Million USD | 36.56% |
| 2018 FY | 9.5 Million USD | -17.07% |
| 2018 Q4 | 9.5 Million USD | -17.11% |
| 2018 Q3 | 11.46 Million USD | -14.58% |
| 2018 Q1 | 9.82 Million USD | -14.23% |
| 2017 FY | 11.45 Million USD | -68.51% |
| 2017 Q4 | 11.45 Million USD | -41.92% |
| 2017 Q2 | 19.61 Million USD | 0.57% |
| 2017 Q1 | 19.5 Million USD | -46.39% |
| 2017 Q3 | 19.72 Million USD | 0.58% |
| 2016 FY | 36.37 Million USD | 5.2% |
| 2016 Q2 | 35.17 Million USD | 0.85% |
| 2016 Q3 | 35.98 Million USD | 2.3% |
| 2016 Q4 | 36.37 Million USD | 1.1% |
| 2016 Q1 | 34.87 Million USD | 0.85% |
| 2015 FY | 34.57 Million USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | 34.57 Million USD | 0.58% |
| 2015 Q3 | 34.37 Million USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q2 | 451.55 Thousand USD | -16.61% |
| 2004 Q1 | 541.48 Thousand USD | 0.0% |
| 2004 FY | 638.02 Thousand USD | 0.0% |
| 2004 Q3 | 682.68 Thousand USD | 51.19% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aurora Cannabis Inc. | 47.57 Million CAD | 99.456% |
| Avicanna Inc. | 95.36 Thousand CAD | -171.597% |
| Avant Brands Inc. | 1.74 Million CAD | 85.123% |
| Cardiol Therapeutics Inc. | 158.53 Thousand CAD | -63.374% |
| Crescita Therapeutics Inc. | 815 Thousand CAD | 68.221% |
| Knight Therapeutics Inc. | 44.01 Million CAD | 99.412% |
| MediPharm Labs Corp. | 69 Thousand CAD | -275.362% |
| OrganiGram Holdings Inc. | 79 Thousand CAD | -227.848% |
| Canopy Growth Corporation | 493.29 Million CAD | 99.947% |
| Willow Biosciences Inc. | 594 Thousand CAD | 56.397% |
| Auxly Cannabis Group Inc. | 81.38 Million CAD | 99.682% |